Telemedicine has transformed weight loss treatments, but recent FDA changes threaten to upend the industry. Dr. Leo Damasco and Phoebe Gutierrez explore the impact of removing GLP-1 medications like tirzepatide and semaglutide from the shortage list, what it means for telehealth companies, and how providers can pivot to stay ahead.